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Introduction {#sec005}
============

Chronic kidney disease (CKD) is an important cause of death worldwide, affecting more than 10% of the population \[[@pone.0132970.ref001]\]. One of the risk factors for developing CKD and worsening renal outcomes is renovascular disease. One of the proposed mechanisms for progressive CKD in patients with renovascular disease is endothelial dysfunction, oxidative stress, and systemic inflammation of the glomerular capillary wall \[[@pone.0132970.ref002]\].

There is evidence that statins may improve renal function and lower proteinuria in many prospective cohort studies, randomized-control trials and meta-analyses \[[@pone.0132970.ref003]--[@pone.0132970.ref005]\]. This could be due to statin's effects of decreased inflammation and improvement of endothelial function \[[@pone.0132970.ref006]\]. However, previous meta-analyses on the effect of statins on renal outcomes were not specifically done in CKD population \[[@pone.0132970.ref007]\]. One meta-analysis analyzed only the renal outcome at the end of treatment and did not examine change in renal function from baseline. Thus, the impact of statins on change in renal function in CKD patients is still unclear \[[@pone.0132970.ref008]\]. In addition, since the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines \[[@pone.0132970.ref009]\] have emphasized different statin intensities in patients with different risk of atherosclerotic cardiovascular disease, we hypothesized that there is a dose-response relationship between statin intensities and renal outcome. Therefore, we conducted a systemic review with a meta-analysis of cohort studies and randomized-controlled trials to determine the effects of statins on change in renal function and protein excretion compared with controls in patients with CKD \[[@pone.0132970.ref010]\].

Materials and Methods {#sec006}
=====================

This systematic review and meta-analysis was conducted and reported according to established guidelines \[[@pone.0132970.ref011],[@pone.0132970.ref012]\] ([S1 Appendix](#pone.0132970.s001){ref-type="supplementary-material"}) and was registered in PROSPERO (registration number: CRD42014013047).

Search Strategy {#sec007}
---------------

Two authors (AS and SU) independently searched published studies indexed in the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, and EMBASE from January 1995 to January 2015. There were no limitations on language or publication date. References of selected retrieved articles were also examined. Sample search terms were: "statin", "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "hmg coa reductase inhibitor", "chronic renal insufficiency", "kidney failure", "CKD". We limited searches to human only. We did not use filter for study design or limit for adults. Search terms that were used are detailed in [S2 Appendix](#pone.0132970.s002){ref-type="supplementary-material"}.

Inclusion and exclusion criteria {#sec008}
--------------------------------

We included all published randomized clinical trials (RCTs), prospective cohort and retrospective cohort studies comparing statins with placebo or no statin therapy for at least 6 months in patients with chronic kidney disease. We included cohort studies to explore renal outcomes and potential side effects from statin use. We excluded reviews, case reports, letters, commentaries, abstracts, and unpublished articles.

We included participants aged 18 years or older who had CKD stages 3 to 4 (defined as eGFR 15--59 ml/min/1.73 m^2^) and had a baseline eGFR, creatinine clearance or protein concentration in urine. Participants who received dialysis, renal replacement therapy or renal transplantation were excluded from the analysis.

Primary outcome was change of eGFR or creatinine clearance from baseline. Secondary outcomes were change in urinary protein concentration, incidence of 50% reduction in eGFR, and incidence of ESRD.

Data Extraction {#sec009}
---------------

Two authors (AS and SU) independently reviewed titles and abstracts of all citations that were identified. After all abstracts were reviewed, data comparisons between investigators were conducted to ensure completeness and reliability. The inclusion criteria were independently applied to all identified studies. Differing decisions were resolved by consensus.

Full-text versions of potentially relevant papers identified in the initial screening were retrieved. If multiple articles from the same study were found, only the article with the longest follow-up period was included. Data concerning study design, participant characteristics, interventions, and outcome measures were independently extracted. We contacted the authors of the primary reports to request any unpublished data. If the authors did not reply, we used the available data for our analyses.

Assessment of Bias Risk {#sec010}
-----------------------

A subjective assessment of methodological quality for RCT's was conducted by two authors (AS and SU) on the following items, in which each component was categorized as having high, low or unclear risk of bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. The quality of cohort studies was evaluated by the same authors using the Newcastle-Ottawa Scale (NOS) \[[@pone.0132970.ref013]\]. The NOS is a quality assessment tool for non-randomized study. It used a "star system" based on three major perspectives: the selection of the study groups (0--4 stars), the comparability of the groups by controlling for first and second most relevant factors (0--2 stars), and the ascertainment of outcome of interest (0--3 stars). A total score of 3 or less was considered poor, 4--6 was considered moderate, and 7--9 was deemed high quality. We excluded studies from our meta-analysis if they had poor quality. Discrepant opinions between authors were resolved by consensus.

Statistical Analysis {#sec011}
--------------------

We performed meta-analysis of RCT and cohort studies separately. We reported the pooled mean difference (MD) of a total change in eGFR, proteinuria, rate of change in eGFR per year between statin group and controls. Pooled risk ratio (RR) of 50% reduction of eGFR and incidence of ERSD were also reported. For the purpose of our meta-analysis, creatinine clearance was considered to be equivalent to eGFR. The extracted studies were excluded from the analysis if they did not present an outcome in each of the intervention groups or did not have enough information required for continuous data comparison.

We also performed a subgroup analysis of statin intensity, which was characterized as "high-intensity", "moderate-intensity", and "low-intensity" statin therapy, using definitions from the recent ACC/AHA guidelines (9). High intensity statins lower LDL-C by approximately ≥ 50%, include atorvastatin 40--80 mg and rosuvastatin 20-(40) mg. Moderate-intensity statins lower LDL-C by approximately 30% to \<50%, include atorvastatin 10-(20) mg, rosuvastatin (5)-10 mg, simvastatin 20--40 mg, pravastatin 40-(80) mg, lovastatin 40 mg, fluvastatin XL 80 mg, fluvastatin 40 mg bid, pitavastatin 2--4 mg. Low-intensity statins lower LDL-C by approximately \<30%, include fluvastatin 20--40 mg, lovastatin 20 mg, simvastatin 10 mg, pitavastatin 1 mg, pravastatin 10--20 mg. Statin and doses that are approved by the U.S. FDA but were not tested in the RCTs reviewed in the guidelines are listed in parentheses.

The heterogeneity of effect size estimates across these studies was quantified using the I^2^ statistic and Q statistic. For Q statistic, substantial heterogeneity was defined as P\<0.1. The I^2^ statistic ranges in value from 0 to 100% (I^2^\<25%, low heterogeneity; I^2^ = 25%--50%, moderate heterogeneity; and I^2^\>50%, substantial heterogeneity). A sensitivity analysis was performed to assess the influence of the individual studies on the overall results by omitting one study at a time. Meta-regression was performed to find source of heterogeneity and to assess association between baseline LDL-C or percent reduction in LDL-C in the statin group and difference in eGFR change. Possible publication bias was assessed using funnel plot and Egger's regression test \[[@pone.0132970.ref014]\] (P\<0.05 was considered significant). All data analyses were performed using the Comprehensive Meta-Analysis 3.3 software from the Biostat, Inc.

Results {#sec012}
=======

Description of Included Studies {#sec013}
-------------------------------

The initial search yielded 4,291 articles ([Fig 1](#pone.0132970.g001){ref-type="fig"}); 4,141 articles were excluded because they were not RCTs or observational studies (1,866 articles), did not involve CKD participants (1,426 articles), included dialysis patients or did not have primary outcome (849 articles). A total of 150 articles underwent full-length review. Data were extracted from ten studies involving total of 18,126 CKD participants for qualitative analysis \[[@pone.0132970.ref015]--[@pone.0132970.ref024]\]. The included studies varied in sample size (38 to 6,245), type and dose of statins used (Fluvastatin 20 mg, Pravastatin 40 mg, Atorvastatin 40--80 mg, Lovastatin 40 mg, and Rosuvastatin 2.5 mg), and duration of treatment (12--64 months). Among the ten included studies, nine were RCT's, and one was a prospective cohort study. Sample size of the included studies ranged from thirty-eight to 6,245. Low, moderate and high-intensity statins were all used in the included studies. The study duration ranged from twelve to sixty-three months. LDL-C reduction from baseline ranged from 7.6% to 40.4%. The characteristics of the ten extracted studies included in this review are outlined in [Table 1](#pone.0132970.t001){ref-type="table"}.

![Results of Information Search.](pone.0132970.g001){#pone.0132970.g001}
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###### Characteristics of included studies.

![](pone.0132970.t001){#pone.0132970.t001g}

  Study                                                                            Design                                              Follow-up period (months)   Characteristics   Participants (n)   Comorbidities                                                                                                    Intervention   Statin intensity   Control                                               Baseline eGFR (ml/min/1.73 m^2^)         Baseline urinary protein excretion (g/day)   Baseline LDL-C (mg/dL)    LDL-C reduction (Statin group)   Side effects[\*](#t001fn004){ref-type="table-fn"}                                                   
  -------------------------------------------------------------------------------- --------------------------------------------------- --------------------------- ----------------- ------------------ ---------------------------------------------------------------------------------------------------------------- -------------- ------------------ ----------------------------------------------------- ---------------------------------------- -------------------------------------------- ------------------------- -------------------------------- --------------------------------------------------- --------------- --------------- ------- ------- -----------------------------
  Yasuda 2004 \[[@pone.0132970.ref015]\]                                           Prospective, open-label RCT                         12                          57                53.8               Japanese (100%)                                                                                                  39             41                 DM (100%)                                             Fluvastatin 20 mg plus diet              Low                                          Dietary                   59 ± 31.2                        60 ± 25.6                                           0.8 ± 1.2       0.7 ± 0.6       170.1   25%     None
  Tonelli 2003 \[[@pone.0132970.ref016]\]                                          Randomized double- blind placebo controlled trial   36                          63                24                 White (97.7%)                                                                                                    345            345                CHD (100%) DM (15.4%)                                 Pravastatin 40 mg                        Moderate                                     Placebo                   53.2 ±6.0                        52.5 ±6.5                                           \-              \-              139.5   32%     None
  Tonelli 2005 \[[@pone.0132970.ref017]\]                                          Randomized double- blind controlled trial           60                          63                23.6               Black (0.5%)                                                                                                     1702           1700               Hypercholesterolemia (100%), CHD (100%), DM (10.6%)   Pravastatin 40 mg                        Moderate                                     Placebo                   52.7 ± 6.1                       52.7 ± 5.9                                          \-              \-              154.0   \-      Non-dermatologic malignancy
  Bianchi 2003 \[[@pone.0132970.ref018]\]                                          Prospective, controlled open-label RCT              12                          55.6              32.1               N/A                                                                                                              28             28                 HTN (48.2%)                                           Atorvastatin 40 mg                       High                                         No atorvastatin           50.8 ± 9.5                       50.0 ± 10.1                                         2.2 ± 0.5       2.1 ± 0.5       203.0   40.4%   N/A
  Kendrick 2009 \[[@pone.0132970.ref019]\]                                         Randomized double- blind placebo controlled trial   64                          62                21.3               African-American (1.3%)                                                                                          145            159                HTN (35.2%), DM (1.6%)                                Lovastatin maximum dose 40 mg            Moderate                                     Placebo                   53 ± 6                           53 ± 6                                              \-              \-              151.0   27%     None
  Rahman 2008 \[[@pone.0132970.ref020]\]                                           Prospective randomized clinical trial               58                          70.7              54.4               White non-Hispanic (50.7), Black non-Hispanic (28.6), White Hispanic (13.9), Black Hispanic (1.4), Other (5.3)   779            778                HTN (100%) DM (30.8%)                                 Pravastatin 40 mg                        Moderate                                     Usual care                50.8 ± 8.2                       50.6 ± 8.4                                          \-              \-              146.5   30.2%   None
  Koren 2009 \[[@pone.0132970.ref021]\]                                            Prospective, open-label RCT                         54                          65.2              23.1               White (88.1%), African-American (8.5%)                                                                           286            293                CHD (100%), DM (28%)                                  Atorvastatin 80 mg                       High                                         Usual care                51.3 ± 7.8                       51.1 ± 8.5                                          \-              \-              148.0   34.5%   N/A
  Sawara 2008 \[[@pone.0132970.ref022]\]                                           Prospective, open-label RCT                         12                          67                47.4               Japanese (100%)                                                                                                  22             16                 CHD (34.2%)                                           Rosuvastatin 2.5 mg                      Moderate                                     No lipid lowering drugs   50.7 ± 18.7                      57.3 ± 16.2                                         0.17 ± 0.29     0.12 ± 0.3      130.3   24.3%   N/A
  Natsuaki 2012[^a^](#t001fn002){ref-type="table-fn"} \[[@pone.0132970.ref023]\]   Prospective cohort                                  31                          71.4              20.8%              Japanese (100%)                                                                                                  2135           2432               CHD (100), HTN (92.6%), DM (54.4%)                    statins                                  N/A                                          No statin                 49.1 ± 7.7                       48.5 ± 8.0                                          \-              \-              119.0   15.9%   N/A
  Natsuaki 2012[^b^](#t001fn003){ref-type="table-fn"} \[[@pone.0132970.ref023]\]   Prospective cohort                                  31                          72                39.8%              Japanese (100%)                                                                                                  229            379                CHD (100), HTN (92.6%), DM (54.4%)                    statins                                  N/A                                          No statin                 22.0 ± 6.2                       20.8 ± 6.7                                          \-              \-              114.0   7.6%    N/A
  Haynes 2014 \[[@pone.0132970.ref024]\]                                           Randomized placebo controlled trial                 48                          63                37.8%              White (71.2%), Black (1.9%), Asian (24.5%), Other (1.9%)                                                         3116           3129               DM (22.8%)                                            Simvastatin 20 mg plus exetimibe 10 mg   Moderate                                     Placebo                   26.6 ± 12.9                      26.6 ± 13.1                                         217 (44--787)   196 (43--746)   111.0   31.0%   N/A

Values are presented as mean ± SD or median (interquartile range).

^a^ Mild CKD (eGFR ≥30-- \<60 ml/min/1.73 m^2^)

^b^ Severe CKD (eGFR \<30 ml/min/1.73 m^2^)

\* Significant side effects (p\<0.05) in the statin group compared with the control group.

Abbreviation: CHD = coronary heart disease, DM = diabetes mellitus, eGFR = estimated glomerular filtration rate, HTN = hypertension, LDL = Low-density lipoprotein, RCT = Randomized controlled trial.

Of these, six studies were included in the meta-analysis for difference in eGFR change \[[@pone.0132970.ref015],[@pone.0132970.ref018],[@pone.0132970.ref020],[@pone.0132970.ref021],[@pone.0132970.ref022]\] and rate of eGFR change per year \[[@pone.0132970.ref016],[@pone.0132970.ref017],[@pone.0132970.ref019],[@pone.0132970.ref020],[@pone.0132970.ref024]\]. Three studies were included in the analysis of difference in proteinuria \[[@pone.0132970.ref015],[@pone.0132970.ref022],[@pone.0132970.ref024]\]. Two studies were included in analysis comparing 50% reduction of eGFR and incidence of ESRD \[[@pone.0132970.ref020],[@pone.0132970.ref024]\]

Risk of Bias of Included Studies {#sec014}
--------------------------------

All RCT and non-randomized prospective controlled studies were assessed for risk of bias (summarized in [S1 Fig](#pone.0132970.s003){ref-type="supplementary-material"}). About one-fourth of the studies had selection bias because of non-randomization or no allocation concealment. In addition, only one-third of studies were double-blinded and had blinding of outcome assessment. The quality of one prospective cohort study \[[@pone.0132970.ref023]\] was evaluated by NOS. It received a total of 8 stars (4 stars for selection, 2 stars for comparability, and 2 stars for ascertainment of outcome).

Meta-analysis Results {#sec015}
---------------------

We performed this meta-analysis to investigate the effects of statins versus placebo or control on eGFR and proteinuria using a random effects model. Since there is only one prospective cohort study \[[@pone.0132970.ref023]\], only RCTs were included in the meta-analyses. There was significant difference in the change in the average end of treatment eGFR for rate of eGFR change per year, but no difference the total change of eGFR ([Fig 2A and 2B](#pone.0132970.g002){ref-type="fig"} **)**. The MD of rate of eGFR change per year was 0.10 ml/min/1.73 m^2^ (95% confidence interval \[CI\]: 0.09 to 0.12). The statistical between-study heterogeneity was absence (I^2^ = 0%, p-value = 0.60). The MD of total change in eGFR was 1.78 ml/min/1.73 m^2^ (95% CI: -0.26 to 3.81). The statistical between-study heterogeneity was statistically significant with an I^2^ of 98% (p-value\<0.01).

![Comparison of eGFR Change Between Statin and Control Groups.\
A) Rate of eGFR Change Per Year (ml/min/1.73 m^2^), B) Total Change in eGFR.](pone.0132970.g002){#pone.0132970.g002}

A meta-analysis of studies examining change in proteinuria was also performed **(** [S2 Fig](#pone.0132970.s004){ref-type="supplementary-material"} **)**. There was no significant change in urinary protein excretion with a MD of 0.19 gm/day (95% CI: -0.02 to 0.40). There was significant heterogeneity between the included studies in this meta-analysis (I² = 90%).

Only two studies were included in the analysis of comparison in incidence of ESRD and 50% reduction of eGFR or ESRD between statin and control groups. There were no significant association between statin group and control with ESRD (RR = 0.97, 95% CI: 0.90 to 1.06), and 50% reduction of eGFR (RR = 0.93, 95% CI: 0.86 to 1.01) ([S3A and S3B Fig](#pone.0132970.s005){ref-type="supplementary-material"}).

The results of our subgroup analysis of statin intensity is shown ([Fig 3](#pone.0132970.g003){ref-type="fig"}). There was a significant increase in eGFR in studies of high-intensity statin (LDL-C reduction = 34%-40%) compared with control: the MD of total change in eGFR was 3.35 ml/min/1.73 m^2^ (95% CI: 0.91 to 5.79). No statistically significant difference of change in eGFR was found with moderate- (LDL-C reduction = 24%-32%) and low- (LDL-C reduction = 25%) intensity statin therapy. There were insufficient data to investigate effects of statins intensities on proteinuria.

![Subgroup Analysis of Total Change in eGFR (ml/min/1.73 m^2^) in High, Moderate and Low Intensities Statin Groups.](pone.0132970.g003){#pone.0132970.g003}

Sensitivity Analysis {#sec016}
--------------------

To assess the stability of the results of the meta-analysis of comparison in total change of eGFR and rate of eGFR change, sensitivity analyses were conducted by excluding one study at a time. None of the results was significantly altered, indicating that our results were robust.

Meta-regression {#sec017}
---------------

We performed meta-regression analysis using random-effects model to explore the effects of covariates (percent reduction in LDL and baseline LDL) on differences in total change of eGFR. Percent reduction in LDL-C was significant with a coefficient of -9.9 (95% CI: -18.2 to -1.5), p = 0.02, and R^2^ = 60% ([S4 Fig](#pone.0132970.s006){ref-type="supplementary-material"}). In the model that explored effects of baseline LDL-C on change in eGFR, it was a significant predictor with a coefficient of 0.04 (95% CI: 0.03 to 0.05, p\<0.01 and R^2^ = 98%.

Publication Bias {#sec018}
----------------

To investigate potential publication bias, we examined the contour-enhanced funnel plot of the included studies in assessing total change in eGFR. Vertical axis represents study size (standard error) while horizontal axis represents effect size (log odds ratio). From this plot, bias is not present because there is symmetrical distribution of studies on both sides of the mean. The results of Egger's test suggest that no evidence of publication bias was observed (P = 0.58). The funnel plot for assessing change in proteinuria was not performed due to too few studies.

Discussion {#sec019}
==========

Summary of the Main Results {#sec020}
---------------------------

Overall, our systematic review and meta-analysis in CKD participants found that high-intensity statin therapy \[[@pone.0132970.ref018],[@pone.0132970.ref021]\] had a significantly less reduction in eGFR compared to control. The total difference in eGFR was 3.35 ml/min/1.73 m^2^ in the high-intensity statin group compared with control. However, we found no difference with moderate- and low-intensity statin therapy. In addition, we did not find that statins lowered proteinuria compared to the control group.

Agreements and Disagreements with Other Studies or Reviews {#sec021}
----------------------------------------------------------

Our findings are consistent with other meta-analysis in CKD participants not requiring dialysis \[[@pone.0132970.ref025],[@pone.0132970.ref026]\], which found marginal benefits of statins on change in GFR compared with controls. However, those meta-analyses found a greater reduction of proteinuria in the statin group. We believed that the difference in our findings could be due to a difference in inclusion and exclusion criteria of eligible studies.

Previous meta-analyses of studies that reported renal function found that the effect of statins on eGFR may be dose-related in a general population \[[@pone.0132970.ref007]\]. However, our study is unique in that our findings were specifically done in CKD participants with baseline eGFR less than 60 ml/min/1.73 m^2^. It is possible that CKD patients had greater baseline renovascular disease and therefore required the greater effect of high intensity statins to provide a benefit on renal vasculature and to reduce greater oxidative stress. In addition, we demonstrated that LDL-C reduction had a significant association with change in eGFR. There is an increased change of eGFR with a greater reduction of LDL-C. This analysis helps to confirm a higher change of eGFR in high-intensity statins that had greater reduction of LDL-C compared with moderate- and low-intensity statins. Underlying mechanism of increased change of eGFR might be related to a higher reduction of oxidized LDL particles that normally cause renal and vascular damage. We also found an increased change of eGFR in higher baseline LDL-C. Higher baseline LDL-C may cause more renal injury than lower LDL-C. More severe renal injury may benefits from statin therapy more than lower injury \[[@pone.0132970.ref027],[@pone.0132970.ref028]\].

Our findings are also unique in that we studied the effects of statin on hard end-points such as ESRD or 50% reduction of eGFR. We did not find a significant association of statins and these outcome. Our findings might be useful for clinicians to use high-intensity statin therapy to slow deterioration in renal function in CKD patients. However, there are no clear benefits of statin therapy on proteinuria. This might be because renal injury from lipotoxicity is independent of proteinuria \[[@pone.0132970.ref029]\].

Strengths and Limitations {#sec022}
-------------------------

Strengths of our study include only enrolling CKD participants with a baseline eGFR less than 60 ml/min/1.73 m^2^ and a comprehensive MEDLINE, EMBASE and Cochrane Databases database search. Also, we included only studies with a treatment duration of at least 6 months, which allowed us to see the longer term effects of statins on renal function. In addition, we analyzed the difference in the change of renal function, and not only the end of treatment outcome as in a previous meta-analysis examining this topic \[[@pone.0132970.ref026]\]. Furthermore, we did a subgroup analysis on statin intensity, which can keep answer whether statins may have a dose-response effect in CKD patients.

There are several limitations in our meta-analysis, and thus our results should be interpreted with caution. First, we included a relatively small number of studies. This is because we separately analyzed studies with the outcome of total change in eGFR and rate of eGFR change per year as they used different units and we did not have enough information to change them into the same unit.

Second, there is high heterogeneity between studies in the meta-analysis of statins effect on total change of eGFR. Potential sources of heterogeneity assessed by meta-regression were study designs, baseline LDL-C, and LDL-C reduction. We found that there was an increased in total change of eGFR with a higher baseline LDL-C or with an increased in reduction of LDL-C. This finding supports our main results of a significant effects of high-intensity statin.

Conclusions {#sec023}
===========

Our results add evidence that statin use in CKD patients may delay progression of kidney disease, and our results suggest that statins may have a dose-related effect on kidney function as only high-intensity statin significantly improved renal function assessed by estimated GFR. However, these results should be interpreted with caution. Further RCT's using different statin intensities in CKD patients not requiring dialysis with a longer duration of study are needed.
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